General Nephrology
General nephrology news, cross-cutting research, and notable developments across the breadth of kidney medicine, curated by ASNRT.
Browse all news
Explore the full ASNRT newsroom for society announcements, KDIGO guideline updates, AJNT issue releases, and notable developments across the breadth of nephrology.
Latest in this topic
The most recent evidence summaries curated by ASNRT on this topic:
APOL1 kidney disease: a critical narrative review of molecular mechanisms, clinical heterogeneity, and the emerging therapeutic landscape. · Targeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. · Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus · Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. · A New Avenue for the Long-Term Upstream Inhibition of the Renin-Angiotensin-Aldosterone System by Inhibiting Angiotensinogen RNA. · Juvenile-onset Systemic Lupus Erythematosus: Recent Advances in Pathogenesis and Treatment. · Long-term outcome and management of complement-mediated thrombotic microangiopathy/aHUS. · CAR-T cell therapy in nephrology. · A Systematic Literature Review of Coordinated Care in Cardiovascular-Kidney-Metabolic Conditions. · Insights into the Mechanism of Action of Tirzepatide: A Narrative Review. · EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. · Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis · Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. · Tirzepatide and Kidney Protection in Obesity: Unanswered Questions. · In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus. · Benefit-harm trade-offs of intensive versus standard blood pressure control: pooled individual-participant analysis · Immunomodulatory effects of anti-diabetic therapies: Cytokine and chemokine modulation by metformin, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists (2013-2025). · Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline · Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis. · Advancements in complement inhibition for PNH and primary complement–mediated thrombotic microangiopathy · APOL1 Mediated Kidney Disease: A Review and Look Toward the Future. · Intensive systolic blood pressure reduction and kidney and cardiovascular outcomes (CRHCP secondary analysis) · Validation of BCMA-CD19 Compound CAR-T Therapy in SLE Overlap Syndrome: Over 1.5-Year Follow-Up. · APOL1 Kidney Disease: Conclusions from a KDIGO Controversies Conference · Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes. · Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome. · Women and kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. · CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes. · Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials · Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes · Amikacin use in critically ill patients requiring renal replacement therapy: the AMIDIAL-ICU study. · Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis. · Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications. · Six-month safety and efficacy outcomes from the randomized-controlled arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial. · [Nephrology : what's new in 2024 (II)]. · Mind the gap in kidney care: translating what we know into what we do. · Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy. · Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials · ISCN 2024 - An International System for Human Cytogenomic Nomenclature (2024). · Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology